COMMUNIQUÉS West-GlobeNewswire

CAMP4 Reports First Quarter 2025 Financial Results and Corporate Highlights
13/05/2025
Phase 1 clinical trial of CMP-CPS-001 in Urea Cycle Disorders (UCDs) ongoing, with dosing completed in multiple ascending dose (MAD) cohort 3; safety, pharmacokinetic, and pharmacodynamic data expected Q4 2025 CTA [...]
Evoke Pharma Reports First Quarter 2025 Financial Results and Provides Business Update
13/05/2025
Q1 2025 Net Product Sales Increased 77% Year-over-Year to $3.1 Million Sustained Momentum Driven by Growing Prescriber Adoption and Repeat Patient Use SOLANA BEACH, Calif., May 13, 2025 (GLOBE NEWSWIRE) -- Evoke Pharma [...]
Avadel Pharmaceuticals Expands Leadership Team with Appointment of Susan Rodriguez as Chief Operating Officer
13/05/2025
DUBLIN, May 13, 2025 (GLOBE NEWSWIRE) -- DUBLIN, May 13, 2025 – Avadel Pharmaceuticals plc (Nasdaq: AVDL), a biopharmaceutical company focused on transforming medicines to transform lives, today announced the [...]
Checkpoint Therapeutics Reports First Quarter Financial Results and Recent Corporate Updates
13/05/2025
UNLOXCYT™ (cosibelimab-ipdl) approved by U.S. FDA in December 2024 as first and only anti-PD-L1 treatment for advanced cutaneous squamous cell carcinoma Special meeting of stockholders to vote on Merger to take place on [...]
Tempest Reports First Quarter 2025 Financial Results and Provides Business Update
13/05/2025
Presented new amezalpat mechanism-of-action data reinforcing its potential as a novel cancer treatment at the 2025 AACR Annual Meeting Granted Orphan Drug designation by FDA for TPST-1495 for the treatment of familial [...]
Metagenomi Reports Business Updates and First Quarter 2025 Financial Results
13/05/2025
- Nonhuman primate (NHP) study in hemophilia A demonstrated therapeutically relevant factor VIII (FVIII) activity with durable response through approximate ly 19 months with an encouraging safety profile - Well [...]
Vivani Medical Provides Business Update Including $3M Equity Financing and Reports First Quarter 2025 Financial Results
13/05/2025
All subjects in the NPM-115 cohort had successful insertions of a miniature, ultra long-acting GLP-1 (exenatide) implant in the on-going LIBERATE-1™ study in obese or overweight individuals; top-line results are [...]
Annovis Provides Corporate Updates and Reports First Quarter 2025 Financial Results
13/05/2025
Malvern, Pa., May 13, 2025 (GLOBE NEWSWIRE) -- Annovis Bio Inc. (NYSE: ANVS) ("Annovis" or the “Company”), a late-stage clinical drug platform company pioneering transformative therapies for neurodegenerative diseases [...]
Silexion Therapeutics Reports First Quarter 2025 Financial Results and Provides Business Update
13/05/2025
Significant advancements in preclinical pipeline for SIL204, with groundbreaking data demonstrating efficacy against both primary tumors and metastases in orthotopic models; strengthened financial position with over $9 [...]
Scientific Industries Reports Financial Results for First Quarter of Fiscal Year 2025
13/05/2025
BENCHTOP LAB EQUIPMENT SALES UP 5% FIRST PEER-REVIEWED PUBLICATION ON COMPANY’S DOTS MPS BIOPROCESSING PLATFORM RECORD NUMBER OF BIOPROCESSING SALES OPPORTUNITIES Investor Call to be held Wednesday, May 14 th at 11:00 a [...]
Applied Therapeutics Reports First Quarter 2025 Financial Results
13/05/2025
- Company to present full 12-month clinical data and new topline 18-month and 24-month data from INSPIRE registrational Phase 3 trial of govorestat in CMT-SORD Deficiency at the Peripheral Nerve Society 2025 Annual [...]
Claritas Neurocloud™ for Brain Imaging Analysis to Commence Commercialization on Execution of Partnership between Claritas and Qubiotech
13/05/2025
LONDON and SAO PAULO, May 13, 2025 (GLOBE NEWSWIRE) -- Claritas HealthTech Limited (“Claritas”), a healthcare technology company specializing in advanced medical image processing, segmentation, and AI solutions for the [...]
COSCIENS Biopharma Inc. Reports First Quarter 2025 Financial Results and Provides a Corporate Update
13/05/2025
Repositioned as a pure-play natural-based product company following strategic review and pipeline prioritization Efforts continue to gain efficiencies through streamlining and cost cutting measures; Company ended the [...]
Anteris Announces Results for the First Quarter of 2025
13/05/2025
MINNEAPOLIS and BRISBANE, Australia, May 13, 2025 (GLOBE NEWSWIRE) -- Anteris Technologies Global Corp. ( Anteris or the Company ) (NASDAQ: AVR, ASX: AVR) a global structural heart company committed to designing, [...]
Neo Medical and POCUS Certification Academy Launch Forward-Thinking Device and Education Bundle
13/05/2025
All-in-one solution provides an accessible pathway for clinicians at all levels and specialties to improve diagnostic accuracy, patient care, and clinical outcomes ROCKVILLE, Md., May 13, 2025 (GLOBE NEWSWIRE) -- Neo [...]
Best Creatine For Women: Top Creatine Supplements For Muscle Growth & Female Athletes
13/05/2025
Discover the best creatine supplements for women over 40. Support muscle growth, energy, and performance with top-rated creatine picks for female athletes and active women by Crazy Nutrition’s Ultimate CRN-5. Glasgow, [...]
Best HGH for Men to Buy Online: Natural HGH for Sale for Men - Legal Human Growth Hormone for Muscle Growth and Fat Loss - CrazyBulk
13/05/2025
New York City, NY, May 13, 2025 (GLOBE NEWSWIRE) -- Looking for the best HGH for men to buy online? Natural HGH supplements are the ultimate solution for men seeking to boost muscle growth, burn stubborn fat, and [...]
Lexicon Pharmaceuticals Reports First Quarter 2025 Financial Results and Provides Business Updates
13/05/2025
Company had a strong start to 2025, emerging as an R&D-focused organization Exclusive license agreement with Novo Nordisk for LX9851 executed; IND-enabling studies on track for completion in 2025 Phase 2b PROGRESS [...]
Athira Pharma to Present Data from First-in-Human Phase 1 Clinical Trial of ATH-1105 at the 4th Annual ALS Drug Development Summit
13/05/2025
Data from Phase 1 clinical trial of ATH-1105 in healthy volunteers showed a favorable safety and tolerability profile; dose proportional pharmacokinetics and CNS penetration support continued clinical development On- [...]

Pages